Researchers Backpedal From Their Own Risperdal Study
11/20/2013 In the wake of the $2.2 billion settlement by Johnson & Johnson to resolve criminal and civil charges for illegal marketing of the Risperdal antipsychotic pill (more here), two of the authors of a medical paper that was used to inappropriately market the medicine are back peddling from the publication, according to The Chronicle of […]
